| Compound | NAD+ |
|---|---|
| Category | Coenzyme (injectable use unapproved) |
| Class | Metabolic and Mitochondrial Compounds |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers NAD+, a coenzyme (injectable use unapproved), graded "Clinical-stage" in this catalog's evidence system. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
The essential redox coenzyme nicotinamide adenine dinucleotide. Oral precursor supplements are established; intravenous NAD+ infusions remain an unapproved wellness practice with early-phase research only.
Mechanism of Action
NAD+ is central to redox metabolism and serves as substrate for sirtuins and PARPs; tissue NAD+ declines with age in animal models.
Research and Evidence
Small human studies of IV NAD+ report pharmacokinetics and subjective effects; precursor trials (nicotinamide riboside etc.) show NAD+ elevation but mixed clinical outcomes.
Safety and Side Effects
Infusion-tolerance data are limited; wellness-clinic use lacks the pharmacovigilance of approved products.
Frequently Asked Questions
What is the evidence tier of NAD+?
NAD+ is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is NAD+ an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for NAD+?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered NAD+ studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.